Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Non-Current Assets (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Non-Current Assets readings, the most recent being $41000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 90.33% year-over-year to $41000.0, compared with a TTM value of $864000.0 through Dec 2025, down 60.82%, and an annual FY2025 reading of $41000.0, down 90.33% over the prior year.
  • Non-Current Assets hit $41000.0 in Q4 2025 for Lisata Therapeutics, down from $184000.0 in the prior quarter.
  • The five-year high for Non-Current Assets was $1.0 million in Q1 2023, with the low at $41000.0 in Q4 2025.
  • Median Non-Current Assets over the past 3 years was $550000.0 (2024), compared with a mean of $555416.7.
  • The sharpest move saw Non-Current Assets plummeted 33.75% in 2024, then tumbled 90.33% in 2025.
  • Year by year, Non-Current Assets stood at $770000.0 in 2023, then plummeted by 44.94% to $424000.0 in 2024, then plummeted by 90.33% to $41000.0 in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $41000.0, $184000.0, and $275000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.